Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
Adult
Alkynes
/ administration & dosage
Anti-HIV Agents
/ administration & dosage
Antiretroviral Therapy, Highly Active
/ adverse effects
Arthralgia
/ chemically induced
Benzoxazines
/ administration & dosage
Cross-Sectional Studies
Cyclopropanes
/ administration & dosage
Erectile Dysfunction
/ chemically induced
Female
HIV
/ drug effects
HIV Infections
/ drug therapy
Heterocyclic Compounds, 3-Ring
/ administration & dosage
Humans
Longitudinal Studies
Male
Middle Aged
Nausea
/ chemically induced
Oxazines
/ administration & dosage
Patient Reported Outcome Measures
Piperazines
/ administration & dosage
Pyridones
/ administration & dosage
Quality of Life
/ psychology
Registries
Sweden
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
06
2020
accepted:
07
11
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
20
1
2021
Statut:
epublish
Résumé
The use of patient-reported outcomes (PROs) to systematically quantify adverse events (AE) will assist in the improvement of medical care and the QoL of patients living with HIV (PLWH). The aim of this study was to investigate the associations between self-reported side effects and other PROs, demographics and laboratory data, and further evaluate the Health Questionnaire (HQ) as a tool for following trends in patient-reported side effects over time in relation to trends in prescribed third agent in ART. The Swedish National Registry InfCareHiv includes an annual self-reported nine-item HQwhich is used in patient-centered HIV care in all Swedish HIV units. In this study, the experience of side effects was addressed. We analyzed 9,476 HQs completed by 4,186 PLWH together with details about their prescribed ART and relevant biomarkers collected during 2011-2017. Data were analyzed using descriptive statistics, Pearson's correlation coefficient and mixed logistic regression. The cross-sectional analysis of the HQs showed that the frequency of reported side effects decreased from 32% (2011) to 15% (2017). During the same period, there was a shift in ART prescription from efavirenz (EFV) to dolutegravir (DTG) (positive correlation coefficient r = 0.94, p = 0.0016). Further, PLWH who reported being satisfied with their physical health (OR: 0.47, p = <0.001) or psychological health (OR: 0.70, p = 0.001) were less likely to report side effects than those less satisfied. Self-reported side effects were found to have a close relationship with the patient's ratings of their overall health situation and demonstrated a strong correlation with the sharp decline in use of EFV and rise in use of DTG, with reported side effects being halved. This study supports the feasibility of using the HQ as a tool for longitudinal follow up of trends in PROs.
Identifiants
pubmed: 33362248
doi: 10.1371/journal.pone.0242710
pii: PONE-D-20-19335
pmc: PMC7757802
doi:
Substances chimiques
Alkynes
0
Anti-HIV Agents
0
Benzoxazines
0
Cyclopropanes
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
dolutegravir
DKO1W9H7M1
efavirenz
JE6H2O27P8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0242710Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Rehabil Med. 2002 Sep;34(5):239-46
pubmed: 12392240
BMJ Open. 2014 Sep 19;4(9):e005992
pubmed: 25239295
J Asthma. 2008 Oct;45(8):664-9
pubmed: 18951257
Dtsch Arztebl Int. 2012 Jun;109(26):459-65
pubmed: 22833756
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32
pubmed: 19920223
Scand J Infect Dis. 2014 Jun;46(6):401-11
pubmed: 24754479
PLoS One. 2017 Feb 16;12(2):e0171227
pubmed: 28207816
J Psychopharmacol. 2012 Dec;26(12):1540-7
pubmed: 22992377
EMBO Rep. 2016 Jul;17(7):949-52
pubmed: 27198546
Crit Care. 2014 Nov 25;18(6):643
pubmed: 25529263
CA Cancer J Clin. 2007 Sep-Oct;57(5):278-300
pubmed: 17855485
Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):731-741
pubmed: 28176407
Health Technol Assess. 2011 May;15(20):1-234, iii-iv
pubmed: 21545758
Infect Dis (Lond). 2017 Jan;49(1):1-34
pubmed: 27804313
JAMA. 2002 Dec 18;288(23):3027-34
pubmed: 12479768
Scand J Infect Dis. 2009;41(11-12):788-807
pubmed: 19922061
AIDS Care. 2013;25(4):400-14
pubmed: 22908886
J Clin Oncol. 2004 Feb 15;22(4):714-24
pubmed: 14966096
Curr Med Res Opin. 2016 Dec;32(12):2039-2046
pubmed: 27552553
Hematology Am Soc Hematol Educ Program. 2015;2015:501-6
pubmed: 26637765
AIDS Behav. 2017 Feb;21(2):341-351
pubmed: 27613645
J Antimicrob Chemother. 2009 Sep;64(3):599-606
pubmed: 19602563
PLoS One. 2016 Jun 16;11(6):e0156916
pubmed: 27310201
Lancet HIV. 2017 Jan;4(1):e31-e40
pubmed: 27863996
Lancet HIV. 2020 Jan;7(1):e59-e68
pubmed: 31776101
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19600
pubmed: 25394104
N Engl J Med. 2010 Mar 11;362(10):865-9
pubmed: 20220181
JAMA. 2002 Feb 6;287(5):622-7
pubmed: 11829702
Ann Behav Med. 2011 Feb;41(1):83-91
pubmed: 20922510
PLoS One. 2015 May 01;10(5):e0124279
pubmed: 25933004